Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618098 · ClinicalTrials.gov registry record · Phase 3
Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
A Phase 3 study of Reversal of Anticoagulant Treatment, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00618098 is a Phase 3 study of Reversal of Anticoagulant Treatment that has completed, run by Octapharma. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00618098, a Phase 3 study of Reversal of Anticoagulant Treatment, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Octaplex (human prothrombin complex concentrate) can reverse the effects of anticoagulants when compared to the standard treatment of fresh frozen plasma (FFP).
Conditions Studied
Interventions
- BIOLOGICAL Octaplex (human prothrombin complex concentrate)
- BIOLOGICAL Fresh frozen plasma
Study Locations (1)
Pennsylvania
- Contact Octapharma for Facility details - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618098
The ClinicalTrials.gov registry entry for NCT00618098 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Reversal of Anticoagulant Treatment appearing as the primary indexed condition, and to 2 interventions - of which Octaplex (human prothrombin complex concentrate) is the first listed.
NCT00618098 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00618098 about?
NCT00618098 is a clinical study titled "Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures". The purpose of this study is to determine whether Octaplex (human prothrombin complex concentrate) can reverse the effects of anticoagulants when compared to the standard treatment of fresh frozen plasma (FFP).
What is the current status of trial NCT00618098?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2008-05. Estimated completion is 2012-08.
What conditions does trial NCT00618098 study?
This clinical trial studies the following conditions: Reversal of Anticoagulant Treatment.
What interventions are being tested in trial NCT00618098?
The interventions under investigation include: Octaplex (human prothrombin complex concentrate) (BIOLOGICAL), Fresh frozen plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00618098?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00618098 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.